Ceapro Reports "Record" Financial Results for Q1 2013

By
A A A

Ceapro Inc. (CZO.V) today announced record financial results for the first quarter ended March 31, 2013.

FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2013

- Total sales of $2,012,000 compared to $1,190,000 in Q1, 2012, an increase of 69%

- Net income of $408,000 compared to a net loss of $4,000 in Q1, 2012

- Total comprehensive income of $391,000 compared to a total comprehensive loss of $4,000 for Q1, 2012.

FIRST QUARTER 2013 KEY OPERATIONAL HIGHLIGHTS

- Sucessful development of new avenanthramide and beta glucan prototype products

- Commencement of a new agreement with the National Research Council to conduct in-vitro studies with new prototype products and compare data to existing ones obtained with our current products.

- New collaboration agreement including funding support with an agriculture producer group to support the development of new oat products

- Completion of development plan to multiply new oat variety developed by Agriculture and Agri-Food Canada pursuant to 2012 agreement

- Continued positive development of malting technology to boost avenanthramide contents in oats and Supercritical fluid drying platform using beta glucan.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


This article appears in: Investing , Commodities

Referenced Stocks:

MT Newswires

MT Newswires

More from MT Newswires:

Related Videos

Stocks

Referenced

Most Active by Volume

44,823,339
  • $75.19 ▲ 0.28%
43,744,171
  • $3.44 ▼ 0.29%
42,340,022
  • $97.671 ▲ 0.66%
34,178,145
  • $17.62 ▼ 1.23%
34,028,998
  • $15.59 ▼ 0.19%
32,055,708
  • $21.23 ▼ 2.41%
31,539,235
  • $3.76 ▲ 0.80%
30,434,619
    $34.25 unch
As of 7/25/2014, 04:03 PM